RE:RE:RE:RE:RE:RE:RE:PharmagradeRttt, you have been questioning Medipharms cash position as being fragile for several quarters now, and yet corporate burn has not substantially decreased that cash position from the date of the last financing in March 2021
Obviously they must have a fairly good handle on balancing the corporations burn rate.
As for consolidation worries, there would be no advantage at this time to r/s as they are cashed up with promising projects on the horizon. Not to mention this recent covid / CBD revelation could really add some fireworks if promoted correctly by the company.
Add to that, there is another appox $42 million waiting if the corporation can create enough market interest before March 2023 to push the share price into the .70's
With all that is happening in the global CBD arena, my bet is they surpass that target several fold!